Comparative Pharmacology
Head-to-head clinical analysis: ALA CORT versus HYTONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALA CORT versus HYTONE.
ALA-CORT vs HYTONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topical corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid, thereby reducing prostaglandin and leukotriene synthesis, and exerting anti-inflammatory, antipruritic, and vasoconstrictive effects.
Hydrocortisone (topical) binds to glucocorticoid receptors, activating anti-inflammatory proteins and inhibiting phospholipase A2, thereby reducing prostaglandin and leukotriene synthesis.
Topical: Apply a thin film to affected area 3-4 times daily. Dosage strength: 0.5% cream or ointment.
Topical: Apply cream or ointment to affected area 2-4 times daily. Limit treatment area to less than 50% of body surface area. Maximum duration: 2 weeks unless directed by physician.
None Documented
None Documented
Terminal elimination half-life: 1–2 hours for hydrocortisone (active component), prolonged in liver disease or with concurrent CYP3A4 inhibitors.
30–60 minutes (terminal elimination half-life; short duration requires frequent dosing)
Primarily hepatic metabolism (approximately 95%) followed by renal excretion of inactive metabolites (<5% unchanged). Biliary/fecal excretion is negligible.
Renal (primarily as metabolites; ~25% as unchanged drug) and biliary/fecal
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid